Country

Clinical trials in Israel

Active obesity and GLP-1 studies with at least one location in Israel.

21active studies

11recruiting now

35countries represented

121largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 1, Phase 2

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus

Diabete Type 2Condition

SG Depot 2 mg, SG Depot 4 mgTreatment

Israel1 locations

Mapi Pharma Ltd.Sponsor

Updated 2026-08-20 · NCT07563699See eligibility →

Recruiting nowNot applicable

The Role of Microbiome in Recurrent Obesity Before and After Antibiotic/Placebo Treatment

Obesity, Weight LossCondition

Antibiotic treatment, PlaceboTreatment

Israel1 locations

Weizmann Institute of ScienceSponsor

Updated 2026-08-11 · NCT06681246See eligibility →

Recruiting nowPhase 2

COMMETS- Combination MCI Metabolic Syndrome

Alzheimer Disease, Mild Cognitive ImpairmentCondition

Semaglutide, Intranasal insulinTreatment

Israel1 locations

Rutgers, The State University of New JerseySponsor

Updated 2026-07-27 · NCT06072963See eligibility →

Recruiting nowNot applicable

Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide

Type 2 Diabetes Mellitus in ObeseCondition

Wegovy (2.4 Mg Dose) + exercise & nutrition, Wegovy (2.4 Mg Dose) + usual careTreatment

Israel2 locations

Sheba Medical CenterSponsor

Updated 2026-07-21 · NCT06497595See eligibility →

Recruiting nowNot applicable

Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events

Obesity; DrugCondition

nutritional interventionTreatment

Israel3 locations

Ariel UniversitySponsor

Updated 2025-04-24 · NCT06431308See eligibility →

Recruiting nowNot applicable

Evaluating Family & Community-Based Interventions to Improve Treatment Adherence in Metabolic Health Among Negev Bedouins (EFIT-BED)

Community-Based Participatory ResearchCondition

Healthy lifestyle nutrition, culture and physical activity workshops, Usual careTreatment

Israel1 locations

Ariel UniversitySponsor

Updated 2025-01-28 · NCT06575465See eligibility →

Recruiting nowNot applicable

Database Maintenance for Bariatric Procedures

Obesity, Morbid, Bariatric Surgery CandidateCondition

bariatric surgeryTreatment

Israel1 locations

Sheba Medical CenterSponsor

Updated 2024-04-23 · NCT04040413See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Opening soonPhase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Opening soonNot applicable

Plant vs Animal-based Protein Sources as an Anabolic and Metabolic-protective Options for SO in Older Adults

Sarcopenic Obesity, Obesity and Obesity-related Medical ConditionsCondition

Legume-Based High-Protein Diet + Resistance Training, Meat-Based High-Protein Diet + Resistance TrainingTreatment

Israel1 locations

Tel-Aviv Sourasky Medical CenterSponsor

Updated 2025-06-22 · NCT07030738See eligibility →

Active, not recruitingPhase 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

ObesityCondition

Semaglutide, PlaceboTreatment

Austria, Belgium56 locations

Novo Nordisk A/SSponsor

Updated 2026-08-07 · NCT05726227See eligibility →

Active, not recruitingPhase 3

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 DiabetesCondition

Retatrutide, PlaceboTreatment

Argentina, Brazil76 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06297603See eligibility →

Active, not recruitingPhase 3

SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity

ObesityCondition

Liraglutide, PlaceboTreatment

Belgium, India32 locations

Novo Nordisk A/SSponsor

Updated 2026-07-09 · NCT04775082See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingNot applicable

Mapping Metabolic Organ Plasticity in Energy Adaptation

Overweight , Obesity, Energy MetabolismCondition

Calorie Restriction (CR), Time Restricted Eating (TRE)Treatment

Israel1 locations

Tel Aviv UniversitySponsor

Updated 2026-02-17 · NCT07415213See eligibility →

Active, not recruitingPhase 4

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Type 2 DiabetesCondition

Tirzepatide, Antihyperglycemic medicationTreatment

Argentina, Canada90 locations

Eli Lilly and CompanySponsor

Updated 2025-12-12 · NCT05433584See eligibility →

Active, not recruitingNot applicable

Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

Diabetes Mellitus, ObesityCondition

Routine care for people with diabetes, with or without obesity, in the hospital settingTreatment

Austria, Czechia8 locations

Medical University of ViennaSponsor

Updated 2025-05-08 · NCT06680674See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.